GlaxoSmithKline posts results of Phase 3b study of rMenB+OMV NZ in adolescents
Results for the Phase 3b, open-label study of the meningococcal group B vaccine rMenB+OMV NZ were first posted on ClinicalTrials.gov on November 6, 2026, after enrolling 312 participants. The study evaluated the immune response and safety of a booster dose in healthy 10- to 20-year-old participants who were primed with the vaccine during infancy.
Primary source
ClinicalTrials.gov results record, November 6, 2026
A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old)
Read the source: A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old) clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation